Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Survival Benefit of Neoadjuvant Systemic Chemotherapy in Muscle Invasive Bladder Cancer and Factors Affecting Its Response - Retrospective Study

NCT06727214 is registered in ClinicalTrials.gov with Sara Mahmoud Ahmed Mahmoud as lead sponsor.

NCT NCT06727214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06727214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Survival Benefit of Neoadjuvant Systemic Chemotherapy in Muscle Invasive Bladder Cancer and Factors Affecting Its Response - Retrospective Study
Lead sponsor
Sara Mahmoud Ahmed Mahmoud
Phase
Observational
Overall status
Not yet recruiting
Start date
November 4, 2025
Completion date
December 1, 2026
Enrollment
87 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bladder urothelial carcinoma